Diagnosis and Management of Infantile Hemangiomas in the Neonate

Harter, Nicole; Mancini, Anthony J.

doi:10.1016/j.pcl.2018.12.011

Cited by 39 publications

(46 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Інфантильні гемангіоми в літературі часто описувалися під назвами «полунична гемангіома», «полуничний невус», «полуничний знак», «капілярна гемангіома» та «ювенільна гемангіома» [22,30,44]. Для опису ІГ у 1894 р.…”

Section: класифікація інфантильних гемангіомunclassified

“…Серед судинних мальформацій інфантильні гемангіоми (ІГ) є найчастішими доброякісними пухлинами м'яких тканин, які виявляються у 4-5% немовлят [30,59]. Клінічно ІГ проявляються на другому тижні після народження, проте глибокі гемангіоми можуть залишатися невидимими до 2-4 місяців після народження [22,60].…”

unclassified

See 1 more Smart Citation

Infantile hemangioma

Pereyaslov¹,

Rybalchenko²,

Losev³

2020

View full text Add to dashboard Cite

Infantile hemangioma is one of the most common benign vascular malformations in children. Besides that, some questions about classification, diagnostic, and choice of method of treatment remains the questionable. The modern data about classification, clinical course, diagnostic, and main principles of treatment of infantile hemangioma are presented in this work. In most cases, the uncomplicated clinical course of infantile hemangioma was observed. However, in some patients the complications may arise. Ulceration, obstruction, functional impairment, and disfigurement are the most often complications of infantile hemangioma. Although, most infantile hemangiomas tend to regress spontaneously, some of them required the treatment. Applying of the β-blockers (systemic or topical), laser therapy, and surgery are the main methods that used for the treatment of infantile hemangiomas. Patients with infantile hemangiomas, despite the simplicity of diagnostic, should be treated on specialized centers. Early detection of at-risk infantile haemangioma is a major point, requiring an increased awareness by paediatricians, with the aim to prevent the complications development. However, it was proven the efficacy of propranolol treatment for the all types of infantile hemangiomas, the long-term follow-up studies are needed to assess its safety with regard to neurodevelopment. No conflict of interest was declared by the authors. Key words: infantile hemangioma, diagnostic, treatment.

show abstract

Section: класифікація інфантильних гемангіомunclassified

unclassified

Infantile hemangioma

Pereyaslov¹,

Rybalchenko²,

Losev³

2020

View full text Add to dashboard Cite

show abstract

“…Infantile hemangioma (IH) is a common congenital vascular malformation that affects 4–5% of full-term infants ( Itinteang et al., 2014 ; Grzesik and Wu, 2017 ). The incidence of IH is higher in females than in males, with an estimated ratio of 3–5:1 ( Harter and Mancini, 2019 ; Wildgruber et al., 2019 ). Because of a natural history of spontaneous involution, most IHs do not need treatment ( Harter and Mancini, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

“…The incidence of IH is higher in females than in males, with an estimated ratio of 3–5:1 ( Harter and Mancini, 2019 ; Wildgruber et al., 2019 ). Because of a natural history of spontaneous involution, most IHs do not need treatment ( Harter and Mancini, 2019 ). However, some severe IH cases are associated with complications including bleeding, ulceration, or disfigurement, which require early interventions ( Singh et al., 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Combined Topical Timolol and Oral Propranolol for Treating Infantile Hemangioma: A Meta-Analysis of Randomized Controlled Trials

et al. 2020

View full text Add to dashboard Cite

Background Oral propranolol has become the first-line treatment for infantile hemangioma (IH). However, combined therapy with topical timolol and oral propranolol has been proposed as a more effective IH treatment strategy. We aimed to compare the safety and efficacy of topical timolol, oral propranolol, and their combination for treating IH in a meta-analysis. Methods Relevant randomized controlled trials (RCTs) were obtained after searching the PubMed, Embase, Cochrane’s Library, China National Knowledge Infrastructure, and WanFang databases. A random-effect model was used to pool the results. Results Eight RCTs with 759 patients with IH were included in this meta-analysis. Treatment with topical timolol alone showed a similar response rate compared to oral propranolol (risk ratio [RR] = 0.97, p = 0.63), but resulted in fewer adverse events (RR = 0.36, p = 0.002). Combined treatment with topical timolol and oral propranolol showed a favorable response rate compared to treatment with oral propranolol (RR = 1.14, p = 0.03) or topical timolol (RR = 1.36, p = 0.01) alone. Moreover, combined treatment showed similar risks of adverse events compared to oral propranolol (RR = 0.80, p = 0.24) or topical timolol (RR = 1.31, p = 0.25) alone. Conclusions Combined treatment with topical timolol and oral propranolol may be more effective than either single treatment strategy in patients with IH. Topical timolol alone conferred similar efficacy for IH compared to oral propranolol, but with less incidence of adverse events.

show abstract

“…Infantile hemangiomas (IHs), affecting approximately 10% of infants younger than 1 year old, are true neoplastic proliferations of endothelial cells and the most common type of congenital benign vascular tumors during infancy[1,2]. IHs have a typically characteristic growth curve with an initial proliferation phase for several months followed by a spontaneous regression phase for several years[3-5].…”

Section: Introductionmentioning

confidence: 99%

Noteworthy effects of a long-pulse Alexandrite laser for treatment of high-risk infantile hemangioma: A case report and literature review

Xue

2019

WJCC

View full text Add to dashboard Cite

BACKGROUND We have previously proved that treatment of thick/deep infantile hemangiomas (IHs) with a long-pulse Alexandrite laser was clinically effective and safe. This article aims to investigate the efficiency of long-pulse Alexandrite laser use in treating thick and high-risk IHs located in particular anatomic areas and provides some new data on this issue. CASE SUMMARY A two-month-old girl with a thick and high-risk IH covering most of the right labia majora was examined in this study. The infant received four treatment sessions at 4- to 6-wk intervals with a long-pulse Alexandrite laser with settings as follows: 3 ms pulse duration, 8 mm spot size, 45 to 50 J/cm 2 fluences, and dynamic cooling device (DCD) spray duration of 90 ms with a delay of 80 ms. Following each of the four treatment sessions, the IH showed a remarkable reduction in thickness and size without any sign of relapse. Ten months after the last treatment, the IH had completely regressed without adverse effects. During the laser treatment, no severe side effects were observed; blistering occurred only immediately after treatment and then scabbed over the next day, gradually improving in the following days. CONCLUSION Long-pulse Alexandrite laser treatment may be considered one of the first-line noninvasive therapeutic options for the treatment of thick IH.

show abstract

Diagnosis and Management of Infantile Hemangiomas in the Neonate

Cited by 39 publications

References 74 publications

Infantile hemangioma

Infantile hemangioma

Efficacy of Combined Topical Timolol and Oral Propranolol for Treating Infantile Hemangioma: A Meta-Analysis of Randomized Controlled Trials

Noteworthy effects of a long-pulse Alexandrite laser for treatment of high-risk infantile hemangioma: A case report and literature review

Contact Info

Product

Resources

About